VEGFA and rhegmatogenous retinal detachment: Conjunctival hemorrhage, vitreous floaters, rhegmatogenous retinal detachments, and retinal hemorrhage: Some toxicities are associated with the intraocular administration method and are consistently reported with all available anti-VEGF agents, exhibiting frequencies that do not significantly vary by drug (conjunctival hemorrhage 20–40%, vitreous floaters 5–15%, rhegmatogenous retinal detachments 0.013%, retinal hemorrhage 1–10%) [142,143,144,145].